Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.34 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283955 | 0.98 | MAPT (0.45) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13654389 | 0.81 | BACE1 (0.53) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL17080670 | 0.76 | CYP2A6 (0.58) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL7898110 | 0.76 | CA2 (0.55) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL18878582 | 0.76 | CYP2A6 (0.41) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6121215 | 0.74 | CYP2A6 (0.39) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1530760 | 0.73 | CYP2A6 (0.37) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14756124 | 0.73 | CYP2A6 (0.42) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5646366 | 0.72 | CYP2A6 (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16693109 | 0.72 | CYP2A6 (0.38) | MAPTALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117480172-A | Pharmaceutical compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-10414762-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20190010150-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-10 | — | — | US | disclosed |
| US-9914729-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-03-13 | — | — | US | disclosed |
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2017-06-29 | — | — | US | disclosed |
| US-9433614-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20160022651-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | US | disclosed |
| US-9000008-B2 | Amides of acetic and propionic acids | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-07 | — | — | US | disclosed |
| US-20130338186-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8518967-B2 | Amides of acetic and propionic acids | BAYER HEALTHCARE AG (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-7553851-B2 | Amides of acetic and propionic acids | BAYER HEALTHCARE AG (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | US | disclosed |
| EP-1487835-B1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | BAYER HEALTHCARE AG (DE) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022651-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
| US-20170183339-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
| US-20190010150-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
| US-20090258898-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
| US-20070037844-A1 | 2-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride; nicotinic receptor agonists; cognition activators; learning enhancement; nootropic agents; demetia; cholinergic agents; Alzheimer's disease; brain traumas; stroke; attention deficit disorder; schizophrenia | CHRNA2, CHRNA6, CHRNA5 | CA2 1636/4885HSP90AA1 758/4885MAPT 136/4885 |
| US-10414762-B2 | Amides of acetic and propionic acids | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
| US-20130338186-A1 | AMIDES OF ACETIC AND PROPIONIC ACIDS | HCAR2, HCAR3, NAAA | CA2 157/4885HSP90AA1 1985/4885MAPT 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.